Companies › Acrivon Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Prexasertib (ACR-368) Serine/threonine-protein kinase Chk1 inhibitor; Serine/threonine-protein kinase Chk2 inhibitor | CHEK1, CHEK2 | Phase 2 | Endometrial Adenocarcinoma; Head and Neck Squamous Cell Carcinoma | May 2027 |
| ACR-2316 | – | Phase 1 | Specific Advanced Solid Tumors | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05548296 | Prexasertib (ACR-368) | Phase 2 | Endometrial Adenocarcinoma | Oncology | May 2027 |
| NCT06667141 | ACR-2316 | Phase 1 | Specific Advanced Solid Tumors | Oncology | Aug 2027 |
| NCT06597565 | Prexasertib (ACR-368) | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Aug 2028 |
Cash and short-term investments of $90m on 2026-06-30; operating cash outflow about $72m a year; runway about 15 months at that burn, to Sep 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Cellectar Biosciences Allarity Therapeutics ALX Oncology CNS Pharmaceuticals Eikon Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.